Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 19, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share transactions executed by the GlaxoSmithKline Employee Trust ("the GSK Trust") on behalf of employee plans:
- December 14, 2005: The GSK Trust sold 3,250 Ordinary Shares at GBP 14.6026 per share for participants in the Restricted Share Plan.
- December 14, 2005: The GSK Trust transferred 16,484 Ordinary Shares to participants in the Restricted Share Plan.
- December 16, 2005: The GSK Trust transferred 9,300 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the GSK Trust shares in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned share transactions under Disclosure Rule 3.1.4R(1)(b).
Key Facts for Investor Verification
- Verify the total number of shares sold versus transferred by the GSK Trust during the reporting period.
- Confirm the transaction price of GBP 14.6026 per share against the market price on December 14, 2005.
- Review the specific terms of the GlaxoSmithKline Restricted Share Plan and the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting or exercise conditions triggering these transfers.
- Note that the filing does not contain financial results; investors should refer to the company's Form 20-F or interim reports for financial performance.